The BCL-2 inhibitor venetoclax in combination with an anti-CD20 monoclonal antibody has been tested in three pivotal randomized clinical trials (RCTs) with CLL/SLL patients, the MURANO study and the CLL13 and CLL14 trials [1–3]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.